Vertex Pharmaceuticals, Inc. (VRTX) Reports Q2 Loss of 85c, Beats by 10c
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of ($0.85), $0.10 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $114.42 million, versus $31.62 million reported last year.